{
    "clinical_study": {
        "@rank": "38685", 
        "brief_summary": {
            "textblock": "Background:\n\n        -  Pharmacology is the study of pharmaceutical compounds , and encompasses several\n           parameters, including how the body handles the substance (pharmacokinetics, PK), what\n           the substance does to the body at the molecular level (pharmacodynamics), overall\n           efficacy (response), and any adverse events or toxicity encountered.\n\n        -  The Clinical Pharmacology Program (CPP) within the Center for Cancer Research (CCR) of\n           the National Cancer Institute (NCI) has sensitive, state of the art bioanalytical\n           instrumentation that can accurately and precisely quantitate drug concentrations in\n           plasma.\n\n        -  Currently, the CPP can only analyze samples from clinical trials that have explicit\n           instructions (within the    Pharmacokinetics    section) to do so in the IRB approved\n           protocol.\n\n        -  However, clinical trial protocols without a    Pharmacokinetics    section may still\n           need occasional pharmacokinetic plasma samples drawn and drug concentration\n           measurements performed to help explain unexpected AEs or toxicity.\n\n      Objectives:\n\n      - To obtain PK plasma samples from patients being treated with an investigational agent or\n      FDA approved therapy at the NCI who are exhibiting toxicity that is believed to be due to\n      high drug concentration in order to assess the cause of the toxicity and adverse events.\n\n      Eligibility:\n\n      - Any cancer patients who are currently enrolled in IRB approved clinical trials at the\n      National Cancer Institute are eligible.\n\n      Design:\n\n        -  The CPP will measure the drug plasma concentration (or send the sample out to a third\n           party if the assay is commercially available).\n\n        -  The accrual ceiling for this study is 100 patients. The anticipated accrual rate for\n           this protocol is less than 10 patients per year, and based on the accrual ceiling, the\n           duration of accrual and the total study duration is 5 years."
        }, 
        "brief_title": "Collection of Pharmacokinetic Samples From Patients With Unanticipated Response or Toxicity", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "Background:\n\n        -  Pharmacology is the study of pharmaceutical compounds , and encompasses several\n           parameters, including how the body handles the substance (pharmacokinetics, PK), what\n           the substance does to the body at the molecular level (pharmacodynamics), overall\n           efficacy (response), and any adverse events or toxicity encountered.\n\n        -  The Clinical Pharmacology Program (CPP) within the Center for Cancer Research (CCR) of\n           the National Cancer Institute (NCI) has sensitive, state of the art bioanalytical\n           instrumentation that can accurately and precisely quantitate drug concentrations in\n           plasma.\n\n        -  Currently, the CPP can only analyze samples from clinical trials that have explicit\n           instructions (within the    Pharmacokinetics    section) to do so in the IRB approved\n           protocol.\n\n        -  However, clinical trial protocols without a    Pharmacokinetics    section may still\n           need occasional pharmacokinetic plasma samples drawn and drug concentration\n           measurements performed to help explain unexpected AEs or toxicity.\n\n      Objectives:\n\n      - To obtain PK plasma samples from patients being treated with an investigational agent or\n      FDA approved therapy at the NCI who are exhibiting toxicity that is believed to be due to\n      high drug concentration in order to assess the cause of the toxicity and adverse events.\n\n      Eligibility:\n\n      - Any cancer patients who are currently enrolled in IRB approved clinical trials at the\n      National Cancer Institute are eligible.\n\n      Design:\n\n        -  The CPP will measure the drug plasma concentration (or send the sample out to a third\n           party if the assay is commercially available).\n\n        -  The accrual ceiling for this study is 100 patients. The anticipated accrual rate for\n           this protocol is less than 10 patients per year, and based on the accrual ceiling, the\n           duration of accrual and the total study duration is 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA\n\n        Any cancer patients greater than or equal to 2 years of age who are currently enrolled in\n        IRB approved clinical trials at the National Cancer Institute are eligible.\n\n        Ability of subject or a Legally Authorized Representative (LAR) to understand and the\n        willingness to sign a written informed consent document.\n\n        EXCLUSION CRITERIA\n\n        None anticipated at this time."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154022", 
            "org_study_id": "140128", 
            "secondary_id": "14-C-0128"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PK", 
        "lastchanged_date": "May 31, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2014-C-0128.html"
        }, 
        "location": {
            "contact": {
                "last_name": "For more information at the NIH Clinical Center contact National Cancer Institute Referral Office", 
                "phone": "888-624-1937"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Collection of Pharmacokinetic Samples From Patients With Unanticipated Response or Toxicity", 
        "overall_contact": {
            "email": "carterp@ninds.nih.gov", 
            "last_name": "Paula Carter", 
            "phone": "(301) 435-5406"
        }, 
        "overall_contact_backup": {
            "email": "wdfigg@helix.nih.gov", 
            "last_name": "William D Figg, Pharm.D.", 
            "phone": "(301) 402-3622"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "William D Figg, Pharm.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To obtain PK sample", 
            "safety_issue": "Yes", 
            "time_frame": "study completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}